The prior phase III trial evaluating LP-300 with paclitaxel/cisplatin demonstrated a marginal increase in survival in the overall study population. Patients who received TKIs as a prior therapy must have disease progression or treatment intolerance. Enrollment for this trial began in March of 2023.

10 months ago

Clinical • P2 data

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase) • GLRX (Glutaredoxin)

MET exon 14 mutation

cisplatin • carboplatin • paclitaxel • pemetrexed • Tavocept (dimesna)

over1year

HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (clinicaltrials.gov)

P2, N=90, Recruiting, Lantern Pharma Inc. | Not yet recruiting --> Recruiting

over 1 year ago

Enrollment open • Combination therapy

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)

MET exon 14 mutation

carboplatin • pemetrexed • Tavocept (dimesna)

almost2years

HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (clinicaltrials.gov)

P2, N=90, Not yet recruiting, Lantern Pharma Inc.

almost 2 years ago

New P2 trial • Combination therapy

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)

MET exon 14 mutation

carboplatin • pemetrexed • Tavocept (dimesna)